Literature DB >> 34907035

O-GlcNAcylation of Blimp-1 in Lymphocytes Inhibits Its Transcriptional Function and Is Associated with Migration and Invasion of Breast Cancer Cells.

Yan-Fang Chen1, Guang-Can Shao2,3,4, Jie Li5, An-Qi Yang1, Jing Li5, Xin-Shan Ye1.   

Abstract

Lymphocyte infiltration is an important feature of cancer. There is a complex network of chemokines that influence the degree and phenotype of lymphocyte infiltration, as well as the growth, survival, migration, and angiogenesis of tumor cells. High heterogeneity metastasis is a major obstacle to the treatment of breast cancer. Herein, we showed that O-GlcNAcylation of B lymphocyte-induced maturation protein-1 (Blimp-1) in lymphocytes inhibited the migration and invasion of breast cancer cells. It was found that Blimp-1 O-GlcNAcylation at Ser448 and Ser472 in lymphocytes promoted its nuclear localization, and blocked the bindings to three regions upstream of the ccl3l1 promoter to inhibit its expression. Decreased expression of CCL3L1 in lymphocytes not only decreased CCR5 expression in breast cancer cells, but also inhibited the membrane localization and activation of CCR5, thus blocking the migration and invasion of breast cancer cells in vitro. Therefore, O-GlcNAcylation of Blimp-1 in lymphocytes may serve as a new target for the treatment of metastatic breast cancer. IMPLICATIONS: This study reveals a new mechanism by which the lymphatic system promotes breast cancer cell metastasis. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34907035     DOI: 10.1158/1541-7786.MCR-21-0405

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  1 in total

1.  Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.

Authors:  Nicole E James; Morgan Woodman; Payton De La Cruz; Katrin Eurich; Melih Arda Ozsoy; Christoph Schorl; Linda C Hanley; Jennifer R Ribeiro
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.